Reduction in lesions from Lmax: a new concept for assessing efficacy of field-directed therapy for actinic keratosis. Results with imiquimod 3.75% | Zendy

Eggert Stockfleth | Zendy; G. Gupta | Zendy; Ketty Peris | Zendy; S. Aractingi | Zendy; Rada Dakovic | Zendy; Agustı́n Alomar | Zendy

Open Access

Reduction in lesions from Lmax: a new concept for assessing efficacy of field-directed therapy for actinic keratosis. Results with imiquimod 3.75%

Author(s) -

Eggert Stockfleth,

G. Gupta,

Ketty Peris,

S. Aractingi,

Rada Dakovic,

Agustı́n Alomar

Publication year - 2014

Publication title -

european journal of dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.48

H-Index - 71

eISSN - 1952-4013

pISSN - 1167-1122

DOI - 10.1684/ejd.2014.2265

Subject(s) - actinic keratosis , medicine , imiquimod , dermatology , keratosis , pathology , basal cell

Current parameters for assessing the efficacy of actinic keratosis (AK) treatments compare clinical lesions at the start and end of a study. However, the sun-exposed field also contains subclinical lesions which may become detectable during treatment. Lmax, the maximum lesion count during treatment, is a new concept to better assess the efficacy of field-directed AK therapies. Measuring efficacy using the reduction in lesions from Lmax includes for the first time the clearance of both subclinical and clinical lesions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research